Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome

NCT05149898 is registered in ClinicalTrials.gov with Harmony Biosciences Management, Inc. as lead sponsor.

NCT NCT05149898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05149898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome
Lead sponsor
Harmony Biosciences Management, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2020
Completion date
November 9, 2022
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

22q11.2 deletion syndrome